Market Forecast
Registering a CAGR of 8.57%, Transarterial Chemoembolization (TACE) Market is expected to grow from USD 1559.20 Million in 2018 to USD 2777.22 Million by 2025.
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and occurs mainly due to chronic liver disease and cirrhosis. It is the third leading cause of cancer deaths worldwide, with over 500,000 people affected. Transarterial chemoembolization market is the current standard of therapy for patients with intermediate-stage hepatocellular carcinoma (HCC). Conventional TACE is considered as a standard treatment for HCC.
Segmentation
By Product Type
- Chemotherapeutic Agents: Held the largest market share in 2018. Doxorubicin, cisplatin, and mitomycin are most commonly used in the TACE procedure. Doxorubicin is the most widely used chemotherapeutic agent for TACE of HCC. The dose of doxorubicin generally ranges from 30 to 75 mg/m2
- Radiotherapeutic Agents: TACE with radiotherapeutic agents is the most expensive treatment for liver tumors.
- Drug-eluting Particles: Drug-eluting beads have been imposed as novel drug-delivering agents for TACE. DC Beads is one of the most commonly used Drug-eluting beads. These beads are nonbiodegradable PVA microspheres, loaded with calibrated doxorubicin
By End-User
- Hospitals & Clinics: It holds the largest market share that can be attributed to an increase in the number of patients afflicted by HCC, coupled with a rise in a number of hospitals, and quality care, and availability of skilled and qualified professionals.
- Cancer Research Centers: This is the fastest-growing segment due to increasing research funding for the development of effective treatment of HCC
Key Players
- Advaxis Inc. (US)
- Baxter (US)
- Bellicum Pharmaceuticals, Inc. (US)
- Boston Scientific Corporation (US)
- Cook (US)
- Hikma Pharmaceuticals PLC (UK)
- Isofol Medical AB (Sweden)
- Nippon Kayaku Co., Ltd. (Japan)
- Novartis (Switzerland)
- Pfizer (US)
- Sirtex SIR-Spheres Pty Ltd. (Australia)
- Spectrum Pharmaceuticals, Inc. (US)
- Jiangsu Hengrui Medicine Co., Ltd (China)
By Region
- Americas
- Europe
- Asia-Pacific
- Middle East & Africa
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
